Public Employees Retirement System of Ohio Increases Stake in Cytokinetics, Inc. (CYTK)

Public Employees Retirement System of Ohio lifted its stake in shares of Cytokinetics, Inc. (NASDAQ:CYTK) by 34.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 83,387 shares of the biopharmaceutical company’s stock after purchasing an additional 21,268 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.15% of Cytokinetics worth $527,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in CYTK. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Cytokinetics by 141.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,426 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 2,594 shares in the last quarter. Neuburgh Advisers LLC raised its holdings in shares of Cytokinetics by 55.6% during the fourth quarter. Neuburgh Advisers LLC now owns 6,776 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,420 shares in the last quarter. Flinton Capital Management LLC raised its holdings in shares of Cytokinetics by 55.6% during the fourth quarter. Flinton Capital Management LLC now owns 10,472 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 3,740 shares in the last quarter. Jefferies Group LLC purchased a new stake in shares of Cytokinetics during the third quarter worth $110,000. Finally, Virtu Financial LLC purchased a new stake in shares of Cytokinetics during the third quarter worth $111,000. Institutional investors and hedge funds own 71.79% of the company’s stock.

NASDAQ CYTK opened at $8.49 on Tuesday. Cytokinetics, Inc. has a fifty-two week low of $5.75 and a fifty-two week high of $10.44. The company has a current ratio of 9.36, a quick ratio of 9.36 and a debt-to-equity ratio of 1.53.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. The business had revenue of $9.38 million for the quarter, compared to analyst estimates of $3.46 million. Cytokinetics had a negative return on equity of 168.21% and a negative net margin of 337.42%. Research analysts expect that Cytokinetics, Inc. will post -1.75 earnings per share for the current year.

Several analysts recently issued reports on CYTK shares. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of Cytokinetics in a report on Tuesday, March 19th. ValuEngine upgraded Cytokinetics from a “hold” rating to a “buy” rating in a report on Wednesday, March 20th. Zacks Investment Research upgraded Cytokinetics from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Monday, January 21st. Finally, BidaskClub upgraded Cytokinetics from a “hold” rating to a “buy” rating in a report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $13.15.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2019/04/16/public-employees-retirement-system-of-ohio-increases-stake-in-cytokinetics-inc-cytk.html.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Featured Article: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Inc. (NASDAQ:CYTK).

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit